- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01090167
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
A Phase I, Open-label, Multi-center Study of Clofarabine (JC0707) in Japanese Patients With Acute Myeloid Leukemia (AML)
Studieoversikt
Detaljert beskrivelse
This is a Phase I, open-label, multi-center study of Clofarabine administered to Japanese patients with Acute Myeloid Leukemia (AML) who are relapsed/refractory or elderly untreated AML for whom standard induction chemotherapy is unlikely to be of benefit.
Cohort 1 will receive 20 mg/m2/day of Clofarabine once daily for five consecutive days, Cohort 2 will receive 30 mg/m2/day, and Cohort 3 will receive 40 mg/m2/day. Patients will receive one cycle as a rule. However, if there is evidence of some hematologic response after one cycle of treatment with Clofarabine, patients may receive up to a maximum of three cycles. If patients fail to achieve CR or CRp after two cycles of treatment with Clofarabine, further dosing for such patients should be stopped.
Three patients constituting a cohort will receive Clofarabine and will then be assessed for dose limiting toxicities (DLT) at Cycle 1. If none of these three patients develops DLT, the next cohort will be introduced. If one of them develops DLT, three new patients will be added to the cohort, so that six patients in total are included in the tolerability assessment. In this case, treatment of the next cohort is allowed only in the case the number of patients who develop DLT is still one in this six-patient cohort. If two of the six patients develop DLT, however, the tolerability is ruled out. However, if two DLTs are observed at the 20mg/m2/day dose cohort, new patients will be enrolled at cohort -1 15mg/m2/day; and if no more than one of six patients in the cohort develop DLT, it will be considered as the last cohort for this study.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Aichi, Japan
- Nagoya Daini Red Cross Hospital
-
Aichi, Japan
- National Hospital Organization Nagoya Medical Center
-
Fukui, Japan
- University of Fukui Hospital
-
Kanagawa, Japan
- Tokai University Hospital
-
Tochigi, Japan
- Jichi Medical University Hospital
-
Tokyo, Japan
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients having diagnosis of relapsed or refractory Acute Myeloid Leukemia (AML) according to the World Health Organization (WHO) criteria or untreated AML patients (60 years to 74 years) for whom standard induction chemotherapy is unlikely to be of benefit as judged by the investigator (or co-investigator)
- Age at the time of informed consent 20 years up to 74 years; 60 years or older for patients with previously untreated AML
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Be able to comply with the study procedures and follow-up examinations specified in this protocol.
- Hepatic, renal, pancreatic, and cardiac function satisfying the laboratory values criteria
Exclusion Criteria:
- Patients having diagnosis of acute promyelocytic leukemia(APL, French-American-British classification M3 or WHO classification of APL with t(15;17)(q22;q12), (PML/RARA and variants)
- Have had prior hematologic stem cell transplant
- Have had prior external beam radiation therapy to the pelvis
- Have systemic fungal, bacterial, viral, or other infection that cannot be controlled and is exhibiting symptoms related to the infection despite appropriate treatment. In addition, patients must have a temperature less than 38.0 for at least 48 hours prior to the first dose of the study drug.
- Have any other severe concurrent disease that is difficult to control by drug therapies, or have a history of serious organ dysfunction or disease involving the liver, kidney, pancreas, heart, or other organ system that may place the patient at undue risk
- Diagnosis of another malignancy, unless the patient meets none of the following conditions: 1) Any persisting treatment-related adverse events; 2) Less than 180 days of disease-free duration counted during the period from the treatment completion to enrollment; note that the patients meeting any of the following conditions is eligible:
- Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia are eligible for this study if treatment for the condition has been completed.
- Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
- Have a prior positive test for HBs antigen or antibody, HBc antibody, HCV antibody, or HIV antigen or antibody; note that the patients who have had treatment of vaccine and positive for HBs antibody is eligible.
- Have a clinically significant arrhythmia at screening or a known family history of QT prolongation. Marked prolongation of QTc interval exceeding 450 msec is considered clinically significant
- Have clinical evidence suggestive of central nervous system (CNS) involvement with leukemia
- Have a Psychiatric disorders that would interfere with consent, study participation, or follow-up
- Have had prior treatment with the study drug
- Have had any other chemotherapy or investigational agent received within 30 days prior to the first dose of the study drug
- If received any chemotherapy or investigational agent prior to this time point, drug-related adverse events must be recovered to the baseline value or Grade 1 or less prior to the first dose of the study drug (except for alopecia, and nail changes).
- Is currently participating in another concurrent investigational protocol
- Are pregnant or lactating.
- Male and female patients who are fertile must agree to use an effective means of birth control to avoid pregnancy during the study period and for six months after the last dose of study drug.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Klofarabin
|
Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Maximum Tolerated Dose (MTD) as determined by Dose Limiting Toxicities (DLTs)
Tidsramme: 28 days (1st cycle)
|
28 days (1st cycle)
|
Safety as measured by number of patients with at least one adverse events (incidence)
Tidsramme: 50 days
|
50 days
|
Safety as measured by severity of adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by duration of adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by causality of adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by seriousness of adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by type of adverse event
Tidsramme: 50 days
|
50 days
|
Safety as measured by number of deaths
Tidsramme: 50 days
|
50 days
|
Safety as measured by number of serious adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by number of patients who discontinue due to adverse events
Tidsramme: 50 days
|
50 days
|
Safety as measured by clinically significant changes in hematology
Tidsramme: 50 days
|
50 days
|
Safety as measured by clinically significant changes in chemistry parameters (i.e. serum chemistry)
Tidsramme: 50 days
|
50 days
|
Pharmacokinetic (PK) parameters (Cmax, Tmax, AUC)
Tidsramme: 6 days
|
6 days
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CLOAML10508
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Akutt myelogen leukemi
-
Massachusetts General HospitalCelgene CorporationAvsluttetAkutt myelogen leukemi | Akutt myeloid leukemi (AML) | Akutt myelocytisk leukemi | Akutt granulocytisk leukemi | Akutt ikke-lymfocytisk leukemiForente stater
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for...RekrutteringIldfast leukemi | Tilbakefallende leukemi | Akutt myeloid leukemi, barndomKina
-
Betta Pharmaceuticals Co., Ltd.Har ikke rekruttert ennåAkutt Myeloid Leukemi LeukemiKina
-
GlaxoSmithKlineAvsluttetLeukemi, Myelocytisk, AkuttForente stater, Australia, Canada
-
Hybrigenics CorporationUkjentAkutt myelogen leukemiForente stater, Frankrike
-
Massachusetts General HospitalFullført
-
Beijing Boren HospitalRekrutteringAkutt myeloid leukemi | Refraktær Akutt Myeloid Leukemi | Tilbakefall leukemiKina
-
Kinex Pharmaceuticals Inc.FullførtAkutt myelogen leukemiForente stater
-
M.D. Anderson Cancer CenterWake Forest UniversityAvsluttetKronisk myelomonocytisk leukemi | Akutt myelogen leukemiForente stater
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtAkutt monoblastisk leukemi i barndom (M5a) | Akutt monocytisk leukemi i barndom (M5b) | Akutt myeloblastisk leukemi i barndom uten modning (M1) | Akutt myelomonocytisk leukemi i barndommen (M4) | Barndom Akutt Myeloid Leukemi/Andre Myeloid MaligniteterForente stater
Kliniske studier på clofarabine
-
UNC Lineberger Comprehensive Cancer CenterGenzyme, a Sanofi CompanyFullførtAkutt myeloid leukemi | Kronisk myelomonocytisk leukemi | Akutt lymfatisk leukemi | Myelodysplastisk syndromForente stater
-
Baylor Research InstituteGenzyme, a Sanofi CompanyFullførtLeukemi | Myelodysplastisk syndromForente stater
-
Jonsson Comprehensive Cancer CenterAvsluttetOndartet neoplasmaForente stater
-
Jonsson Comprehensive Cancer CenterFullførtLeddgikt | Systemisk lupus erythematosus | Crohns sykdom | Takayasu arteritt | Autoimmun sykdom | Inflammatorisk lidelseForente stater
-
Washington University School of MedicineAvsluttetMultippelt myelomForente stater
-
Ohio State University Comprehensive Cancer CenterFullførtNon-Hodgkins lymfomForente stater
-
M.D. Anderson Cancer CenterGenzyme, a Sanofi CompanyFullført
-
Dana-Farber Cancer InstituteTilbaketrukketLangerhans cellehistiocytose
-
Baylor Research InstituteFullførtMyelodysplastiske syndromer | Akutt myelogen leukemi | Kronisk myelogen leukemiForente stater
-
Dana-Farber Cancer InstituteSanofi; North American Consortium for Histiocytosis; St. Baldrick's Foundation og andre samarbeidspartnereAktiv, ikke rekrutterendeLangerhans cellehistiocytoseForente stater, Canada